

Giuseppe De Luca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11108460/publications.pdf>

Version: 2024-02-01

117
papers

7,100
citations

108046

37
h-index

66518

82
g-index

119
all docs

119
docs citations

119
times ranked

6213
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction. <i>Heart</i> , 2022, 108, 458-466.	1.2	28
2	Immunohistochemical characteristics of coronary thrombi in ST-elevation myocardial infarction. <i>American Heart Journal Plus</i> , 2022, , 100175.	0.3	0
3	Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 140-148.	0.4	5
4	Impact of renin angiotensin system inhibitors on homocysteine levels and platelets reactivity in patients on dual antiplatelet therapy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1276-1285.	1.1	1
5	Association between vitamin D deficiency and serum Homocysteine levels and its relationship with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 523-531.	1.0	13
6	Tratamiento antiagregante de muy corta duraci3n tras la ICP y nuevos SLF: metan3lisis de 5 estudios aleatorizados. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 140-148.	0.6	14
7	Comments on "Sex differences in distribution, management and outcomes of combined ischemic bleeding risk following acute coronary syndrome". <i>International Journal of Cardiology</i> , 2021, 331, 8-9.	0.8	0
8	COVID-19 and Acute Coronary Syndromes: From Pathophysiology to Clinical Perspectives. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-13.	1.9	25
9	Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry. <i>Atherosclerosis</i> , 2021, 332, 48-54.	0.4	28
10	Benefits of short-term or prolonged as compared to standard 1-year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 337-354.	1.0	7
11	Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2321-2330.	1.2	154
12	Impact of gender on immature platelet count and its relationship with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 511-521.	1.0	4
13	ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on "coronary microvascular dysfunction in cardiovascular disease". <i>Cardiovascular Research</i> , 2020, 116, 741-755.	1.8	147
14	Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. <i>Cardiovascular Diabetology</i> , 2020, 19, 215.	2.7	30
15	Statins and Elderly: From Clinical Trials to Daily Practice. <i>Current Vascular Pharmacology</i> , 2019, 17, 233-238.	0.8	3
16	Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients. <i>Pharmacological Research</i> , 2018, 129, 27-33.	3.1	18
17	Impact of statin therapy on the immature platelet count in patients with coronary artery disease: A single centre cohort study. <i>International Journal of Cardiology</i> , 2018, 272, 40-44.	0.8	2
18	Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 173-190.	0.4	16

#	ARTICLE	IF	CITATIONS
19	Field triage in the ambulance versus referral via non-percutaneous coronary intervention centre in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: A systematic review. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 396-403.	0.4	7
20	Radial vs Femoral Approach in Acute Coronary Syndromes: A Meta- Analysis of Randomized Trials. <i>Current Vascular Pharmacology</i> , 2017, 16, 79-92.	0.8	17
21	Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. <i>Platelets</i> , 2016, 27, 1-12.	1.1	5
22	Impact of renal function on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study. <i>Thrombosis Research</i> , 2016, 141, 139-144.	0.8	16
23	Impact of Diabetes on Homocysteine Levels and Its Relationship with Coronary Artery Disease: A Single-Centre Cohort Study. <i>Annals of Nutrition and Metabolism</i> , 2016, 68, 180-188.	1.0	12
24	Everolimus-eluting stent versus Sirolimus-eluting stent for prognostic significance. <i>International Journal of Cardiology</i> , 2016, 202, 940.	0.8	0
25	Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial. <i>EuroIntervention</i> , 2016, 12, 1144-1153.	1.4	3
26	Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated With Acetylsalicylic Acid. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 66, 35-40.	0.8	15
27	Impact of age on mean platelet volume and its relationship with coronary artery disease: A single-centre cohort study. <i>Experimental Gerontology</i> , 2015, 62, 32-36.	1.2	28
28	Elevated Homocysteine and the Risk of Contrast-Induced Nephropathy. <i>Angiology</i> , 2015, 66, 333-338.	0.8	14
29	Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future. <i>Drugs</i> , 2015, 75, 1229-1253.	4.9	29
30	Impact of sex on uric acid levels and its relationship with the extent of coronary artery disease: A single-centre study. <i>Atherosclerosis</i> , 2015, 241, 241-248.	0.4	57
31	Impact of Time from Symptom Onset to Drug Administration on Outcome in Patients Undergoing Glycoprotein IIb-IIIa Facilitated Primary Angioplasty (from the EGYPT Cooperation). <i>American Journal of Cardiology</i> , 2015, 115, 711-715.	0.7	15
32	Bivalirudin as compared to unfractionated heparin in patients undergoing percutaneous coronary revascularization: A meta-analysis of 22 randomized trials. <i>Thrombosis Research</i> , 2015, 135, 902-915.	0.8	17
33	Homocysteine and risk of periprocedural myocardial infarction in patients undergoing coronary stenting. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 100-105.	0.6	5
34	Plateletâ€“larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization. <i>Heart and Vessels</i> , 2015, 30, 20-27.	0.5	8
35	Platelet HPA-1 a/HPA-1 b polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI. <i>Platelets</i> , 2014, 25, 367-372.	1.1	9
36	Smoking and infarct size among STEMI patients undergoing primary angioplasty. <i>Atherosclerosis</i> , 2014, 233, 145-148.	0.4	7

#	ARTICLE	IF	CITATIONS
37	Impact of multivessel disease on infarct size among STEMI patients undergoing primary angioplasty. <i>Atherosclerosis</i> , 2014, 234, 244-248.	0.4	6
38	Platelet distribution width and the risk of periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 345-352.	1.0	12
39	Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors. <i>Heart and Vessels</i> , 2014, 29, 15-20.	0.5	18
40	Preprocedural TIMI flow and infarct size in STEMI undergoing primary angioplasty. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 81-86.	1.0	13
41	Sirolimus-eluting versus paclitaxel-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 355-363.	1.0	5
42	Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study. <i>Thrombosis Research</i> , 2014, 134, 288-293.	0.8	88
43	Platelet PIA1/PIA2 polymorphism and the risk of periprocedural myocardial infarction in patients with acute coronary syndromes undergoing coronary angioplasty. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 107-113.	0.5	7
44	Comprehensive meta-analysis of radial vs femoral approach in primary angioplasty for STEMI. <i>International Journal of Cardiology</i> , 2013, 168, 2070-2081.	0.8	59
45	Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 155-161.	0.7	6
46	Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2090-2099.	1.2	191
47	Mean platelet volume and the risk of periprocedural myocardial infarction in patients undergoing coronary angioplasty. <i>Atherosclerosis</i> , 2013, 228, 136-141.	0.4	22
48	Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the DESERT cooperation. <i>Atherosclerosis</i> , 2013, 230, 12-16.	0.4	15
49	A meta-analytic overview of thrombectomy during primary angioplasty. <i>International Journal of Cardiology</i> , 2013, 166, 606-612.	0.8	137
50	Preinfarction angina does not affect infarct size in STEMI patients undergoing primary angioplasty. <i>Atherosclerosis</i> , 2013, 226, 153-156.	0.4	9
51	Time-to-treatment and infarct size in STEMI patients undergoing primary angioplasty. <i>International Journal of Cardiology</i> , 2013, 167, 1508-1513.	0.8	16
52	Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: Insights from the ACUITY trial. <i>International Journal of Cardiology</i> , 2013, 167, 727-732.	0.8	8
53	Relation of Gender to Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty. <i>American Journal of Cardiology</i> , 2013, 111, 936-940.	0.7	25
54	Impact of Age on Long-Term Outcome After Primary Angioplasty With Bare-Metal or Drug-Eluting Stent (from the DESERT Cooperation). <i>American Journal of Cardiology</i> , 2013, 112, 181-186.	0.7	31

#	ARTICLE	IF	CITATIONS
55	No-Reflow Reversibility: A Study Based on Serial Assessment of Multiple Biomarkers. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 798-807.	1.1	9
56	PLA1/PLA2 polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 411-418.	0.5	33
57	Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 815-820.	0.6	10
58	Impact of Diabetes on Long-Term Outcome After Primary Angioplasty. <i>Diabetes Care</i> , 2013, 36, 1020-1025.	4.3	91
59	Glycoprotein IIb/IIIa Inhibitors. <i>Cardiovascular Therapeutics</i> , 2012, 30, e242-54.	1.1	23
60	Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: A meta-analysis of 8 randomized trials. <i>Atherosclerosis</i> , 2012, 222, 426-433.	0.4	75
61	Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials. <i>Platelets</i> , 2012, 23, 274-281.	1.1	29
62	Treatment algorithm in patients with STEMI. , 2012, , 347-358.		0
63	Treatment algorithm in patients with STEMI. , 2012, , 347-358.		0
64	Clinical impact of simultaneous complete revascularization vs. culprit only primary angioplasty in patients with st-elevation myocardial infarction and multivessel disease: a meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 217-225.	1.0	33
65	Thrombectomy During Primary Angioplasty: Methods, Devices, and Clinical Trial Data. <i>Current Cardiology Reports</i> , 2010, 12, 422-428.	1.3	6
66	Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 23-28.	1.0	12
67	Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 342-346.	1.0	38
68	Thrombus aspiration in primary percutaneous coronary intervention in high-risk patients with ST-elevation myocardial infarction: A real-world registry. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 70-76.	0.7	30
69	Transportation with very long transfer delays (>90 min) for facilitated PCI with reduced-dose fibrinolysis in patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2010, 139, 218-227.	0.8	4
70	Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the POLISH STEMI registry. <i>Atherosclerosis</i> , 2010, 210, 516-520.	0.4	37
71	Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. <i>European Heart Journal</i> , 2009, 30, 2705-2713.	1.0	215
72	Impact of vessel size on distal embolization, myocardial perfusion and clinical outcome in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 198-203.	1.0	14

#	ARTICLE	IF	CITATIONS
73	Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 365-378.	1.0	12
74	Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 288-298.	1.0	12
75	Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2009, 133, 213-222.	0.8	89
76	Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors. <i>American Heart Journal</i> , 2009, 158, 416-421.	1.2	21
77	Percutaneous coronary interventionâ€‘related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. <i>American Journal of Emergency Medicine</i> , 2009, 27, 712-719.	0.7	89
78	Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. <i>American Journal of Emergency Medicine</i> , 2009, 27, 683-690.	0.7	18
79	Benefits From Small Molecule Administration as Compared With Abciximab Among Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Angioplasty. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1668-1673.	1.2	120
80	Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. <i>Atherosclerosis</i> , 2009, 207, 181-185.	0.4	85
81	Routine stenting vs. balloon angioplasty in ST-segment elevation myocardial infarction due to proximal left anterior descending coronary artery occlusion. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 22-26.	0.6	2
82	Transferring Patients With ST-Segment Elevation Myocardial Infarction for Mechanical Reperfusion: A Meta-Regression Analysis of Randomized Trials. <i>Annals of Emergency Medicine</i> , 2008, 52, 665-676.	0.3	112
83	Reperfusion Strategies in Acute ST-Elevation Myocardial Infarction: An Overview of Current Status. <i>Progress in Cardiovascular Diseases</i> , 2008, 50, 352-382.	1.6	72
84	Antithrombotic Therapies in Primary Angioplasty. <i>Drugs</i> , 2008, 68, 2325-2344.	4.9	6
85	Patency of infarct related artery after pharmacological reperfusion during transfer to primary percutaneous coronary intervention influences left ventricular function and one-year clinical outcome. <i>International Journal of Cardiology</i> , 2008, 124, 326-331.	0.8	15
86	Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. <i>International Journal of Cardiology</i> , 2008, 126, 37-44.	0.8	121
87	Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2008, 29, 3002-3010.	1.0	229
88	Cardiogenic shock developing in the coronary care unit in patients with ST-elevation myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 1023-1029.	0.6	17
89	Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: A meta-analysis of randomized trials. <i>American Heart Journal</i> , 2007, 153, 343-353.	1.2	135
90	Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials. <i>American Heart Journal</i> , 2007, 154, 1085.e1-1085.e6.	1.2	28

#	ARTICLE	IF	CITATIONS
91	Comparison between stenting and balloon in elderly patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2007, 119, 306-309.	0.8	13
92	Relationship Between Patient's Risk Profile and Benefits in Mortality From Adjunctive Abciximab to Mechanical Revascularization for ST-Segment Elevation Myocardial Infarction: A Meta-Regression Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2006, 47, 685-686.	1.2	56
93	Comparison between stenting and balloon angioplasty in patients undergoing primary angioplasty of small coronary vessels. <i>American Heart Journal</i> , 2006, 152, 915-920.	1.2	8
94	Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2006, 151, 1256-1259.	1.2	76
95	Impact of routine stenting on myocardial perfusion and the extent of myocardial necrosis in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2006, 151, 1296.e1-1296.e6.	1.2	4
96	Impact of Routine Stenting on Clinical Outcome in Diabetic Patients Undergoing Primary Angioplasty for ST-Segment Elevation Myocardial Infarction. <i>Diabetes Care</i> , 2006, 29, 920-923.	4.3	11
97	Prevention of distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction. A review of current status. <i>Thrombosis and Haemostasis</i> , 2006, 96, 700-10.	1.8	6
98	Relation of Interhospital Delay and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Transferred for Primary Coronary Angioplasty. <i>American Journal of Cardiology</i> , 2005, 95, 1361-1363.	0.7	26
99	Absence of Seasonal Variation in Myocardial Perfusion, Enzymatic Infarct Size, and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Angioplasty. <i>American Journal of Cardiology</i> , 2005, 95, 1459-1461.	0.7	11
100	Homocysteine and Its Effects on In-Stent Restenosis. <i>Circulation</i> , 2005, 112, e307-11.	1.6	18
101	Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1759.	3.8	553
102	Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. <i>European Heart Journal</i> , 2005, 26, 662-666.	1.0	83
103	Commentary. Evidence-based Cardiovascular Medicine, 2005, 9, 286-287.	0.0	0
104	Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. <i>American Heart Journal</i> , 2005, 150, 557-562.	1.2	93
105	Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty. <i>American Heart Journal</i> , 2005, 150, 827-831.	1.2	17
106	Circadian variation in myocardial perfusion and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. <i>American Heart Journal</i> , 2005, 150, 1185-1189.	1.2	56
107	Comparison between ticlopidine and clopidogrel in patients with ST-segment elevation myocardial infarction treated with coronary stenting. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1084-1089.	1.8	9
108	Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. <i>European Heart Journal</i> , 2004, 25, 1009-1013.	1.0	191

#	ARTICLE	IF	CITATIONS
109	Time Delay to Treatment and Mortality in Primary Angioplasty for Acute Myocardial Infarction. <i>Circulation</i> , 2004, 109, 1223-1225.	1.6	1,244
110	Impaired Myocardial Perfusion Is a Major Explanation of the Poor Outcome Observed in Patients Undergoing Primary Angioplasty for ST-Segmentâ€Elevation Myocardial Infarction and Signs of Heart Failure. <i>Circulation</i> , 2004, 109, 958-961.	1.6	62
111	Folate Therapy and In-Stent Restenosis after Coronary Stenting. <i>New England Journal of Medicine</i> , 2004, 350, 2673-2681.	13.9	308
112	Prognostic Assessment of Patients With Acute Myocardial Infarction Treated With Primary Angioplasty. <i>Circulation</i> , 2004, 109, 2737-2743.	1.6	246
113	Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1363-1367.	1.2	141
114	Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: Data from the Zwolle Myocardial Infarction study. <i>American Heart Journal</i> , 2004, 148, 852-856.	1.2	68
115	Outcome in patients treated with primary angioplasty for acute myocardial infarction due to left main coronary artery occlusion. <i>American Journal of Cardiology</i> , 2003, 91, 235-238.	0.7	66
116	Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. <i>Journal of the American College of Cardiology</i> , 2003, 42, 991-997.	1.2	396
117	Direct coronary stenting: Effect on coronary blood flow, immediate and late clinical results. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 53, 464-473.	0.7	66